Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

It fell last week after the company released updated ... term problem for the business. Eli Lilly still has a couple of fantastic drugs in Mounjaro and Zepbound, which could generate a ton of ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Exxon Mobil ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...